65885-27-0 Usage
Uses
Used in Organic Synthesis:
3-Methylsulfonyloxypropanenitrile is used as a reagent in organic synthesis for its role in the formation of carbon-carbon bonds. Its unique chemical properties allow it to facilitate important reactions in the synthesis of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 3-methylsulfonyloxypropanenitrile is used as an intermediate in the production of various drugs. Its versatility and reactivity make it a key component in the synthesis of a range of medicinal compounds.
Used in Agrochemical Production:
3-Methylsulfonyloxypropanenitrile also serves as an intermediate in the production of agrochemicals, contributing to the development of pesticides and other agricultural chemicals that are essential for crop protection and yield enhancement.
Used as a Building Block:
Due to its unique chemical reactivity and structure, 3-methylsulfonyloxypropanenitrile is a versatile building block for the preparation of various compounds. It is utilized in the creation of a wide array of chemical products across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 65885-27-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,8,8 and 5 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 65885-27:
(7*6)+(6*5)+(5*8)+(4*8)+(3*5)+(2*2)+(1*7)=170
170 % 10 = 0
So 65885-27-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H7NO3S/c1-9(6,7)8-4-2-3-5/h2,4H2,1H3
65885-27-0Relevant academic research and scientific papers
2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG
-
Paragraph 00811, (2016/07/05)
The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.
